The Michael Brady Lynch Firm Champions for Onglyza Cardiac Victims
The Michael Brady Lynch Firm’s Lead Trial Attorney and firm founder Michael Brady Lynch, Esq. with Managing Associate Attorney, Jaime E. Moss, Esq. along with associates from Peiffer Rosca Wolf Abdullah Carr & Kane took a stand for victims of Onglyza cardiac injuries by filing with the U.S. District Court for the Eastern District of California
Read More
The Michael Brady Lynch Firm, Premier Onglyza MDL Attorneys
The Michael Brady Lynch Firm tirelessly fights for our clients against corporate greed shown by pharmaceutical companies. The Onglyza litigation taking shape in Lexington, Kentucky is no different. The Michael Brady Lynch Firm and our associates are representing almost one hundred clients who experienced heart failure after taking Onglyza. About Onglyza & Heart Failure Onglyza and Kombiglyze
Read More
Onglyza Heart Failure Lawsuits Centralized in Kentucky
Previously, we mentioned that the Onglyza litigation could be consolidated. The U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered all Onglyza heart failure lawsuits involving Onglyza and also Kombiglyze XR to be centralized before a single judge in the U.S. District Court, Eastern District of Kentucky. About Onglyza & Heart Failure Onglyza and Kombiglyze XR (generic version:
Read More
Onglyza Litigation Moves Forward
The Onglyza litigation is gaining momentum as the U.S. Judicial Panel on Multidistrict Litigation (JPML) heard from attorneys representing Onglyza and Kombiglyze patients when deciding whether to consolidate all federally-filed cases before one court for pre-trial proceedings. About Onglyza & Heart Failure Onglyza and Kombiglyze XR (generic version: saxagliptin) are Type 2 diabetes medications sold
Read MoreFirst Onglyza and Kombligyze XR Heart Failure MDL Filed
More than 40 plaintiffs claiming that Onglyza and Kombiglyze caused their heart failure through lawsuits filed in various districts across the United States, asked that their cases be consolidated into a single multidistrict litigation in California. This will be the first application for an MDL for those who had heart issues from using the medication.
Read More
Onglyza Litigation Update
At The Michael Brady Lynch Firm, we work tirelessly to ensure you receive the most compensation for your injury. Right now, we are working hard to ensure our clients, who experienced heart failure from taking Onglyza, are going to receive their justice in court. The Onglyza litigation is starting to take shape. Onglyza Litigation –
Read More
Express Scripts Drops Onglyza Coverage over Safety Concerns
It should be troubling to all users of Onglyza and Kombiglyze XR that the largest pharmacy benefits manager in the United States, Express Scripts has dropped the Type 2 Diabetes medication. Express Scripts stated that the drug’s side effects were too concerning. Why is a corporation refusing to injury people, yet the FDA still won’t
Read MoreFDA Approves Dangerous Onglyza Cocktail
The FDA has approved a once-daily oral fixed dose medication called Qtern. Qtern combines Onglyza, a DPP-4 inhibitor and an SGLT2 inhibitor called Farxiga. Qtern is for the treatment of Type 2 diabetes. DDP-4 inhibitors like Onglyza are being linked to heart failure while SGLT2 inhibitors like Invokana are being linked to severe kidney damage.
Read More
Onglyza Manufacturer Likely Knew Heart Failure Risk Before Approval
Almost 10% of the U.S. population has Type 2 diabetes. This means big bucks for pharmaceutical companies like AstraZeneca. They knew if they could develop a medication to treat Type 2 diabetes, then they could cash in. Expected annual sales of these drugs will reach $2.47 billion by 2018. Plaintiffs allege that AstraZeneca knew their
Read More
FDA Finally Admits Onglyza Causes Heart Failure
Two years after the FDA promised to look into claims of heart failure in patients taking medications containing saxagliptin such as the popular diabetes medications Onglyza and Kombiglyze XR, the agency at long last acknowledged the risks that consumer advocates have warned about for years. The FDA finally mandated a labeling for all drugs containing
Read More